Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Net Income towards Common Stockholders (2016 - 2025)

China Pharma Holdings' Net Income towards Common Stockholders history spans 16 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders changed 0.19% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$3.2 million, up 32.7%, while the annual FY2025 figure was -$3.2 million, 32.7% up from the prior year.
  • Net Income towards Common Stockholders reached -$1.2 million in Q4 2025 per CPHI's latest filing, down from -$651482.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$475976.0 in Q1 2023 to a low of -$1.4 million in Q2 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$918752.8, with a median of -$857531.5 recorded in 2021.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 6418.56% in 2021, then surged 63.26% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then rose by 0.19% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Net Income towards Common Stockholders are -$1.2 million (Q4 2025), -$651482.0 (Q3 2025), and -$528367.0 (Q2 2025).